Ricin antitoxin - Emergent BioSolutions
Alternative Names: Ricin immunoglobulin - Cangene; Ricin poisoning antidotes; Ricin-IGLatest Information Update: 28 May 2022
At a glance
- Originator Cangene Corporation; Twinstrand Therapeutics
- Developer Emergent BioSolutions
- Class Immunoglobulins; Monoclonal antibodies; Polyclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ricin poisoning
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Ricin poisoning in USA (Parenteral)
- 29 May 2020 Preclinical trials in Ricin poisoning is ongoing in USA (Parenteral) (Emergent BioSolutions pipeline, May 2020)
- 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions